Table 5.
The association of depressive symptoms with kidney function during follow-up, adjusted for competing events
| Entire cohort | Men | Women | ||||
|---|---|---|---|---|---|---|
| Crude additional eGFR over time (95% CI) | Adjusted additional eGFR over timec (95% CI) | Crude additional eGFR over time (95% CI) | Adjusted additional eGFR over timec (95% CI) | Crude additional eGFR over time (95% CI) | Adjusted additional eGFR over timec (95% CI) | |
| (N = 1326) | (N = 1326) | (N = 883) | (N = 883) | (N = 443) | (N = 443) | |
| Presence of depressive symptomsa | 0.05 (–0.01 to 0.11) | 0.05 (–0.02 to 0.11) | 0.05 (–0.04 to 0.14) | 0.05 (–0.04 to 0.14) | 0.00 (–0.16 to 0.16) | 0.00 (–0.15 to 0.16) |
| 10 points decrease in mental health scoreb | –0.01 (–0.03 to 0.00) | –0.01 (–0.03 to 0.00) | –0.01 (–0.03 to 0.01) | –0.01 (–0.03 to 0.01) | 0.00 (–0.04 to 0.03) | 0.00 (–0.04 to 0.03) |
The additional effect on kidney function (95% CI) in mL/min/1.73 m2/month is given for athe presence of depressive symptoms at baseline (i.e. a score ≤70 on the mental health score), and bfor every 10 points decrease in mental health score. cAdjusted for age, sex, ethnicity, level of education, PKD, CCI, BMI, smoking status, SGA, and plasma albumin and urea levels.
*P < 0.05, **P < 0.01.